首页> 外文期刊>JMIR Research Protocols >Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Novel Mobile Phone-Based Intervention: Study Design of a Randomized Controlled Trial
【24h】

Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Novel Mobile Phone-Based Intervention: Study Design of a Randomized Controlled Trial

机译:使用基于手机的新型干预措施,改善口服抗癌药物治疗的癌症患者的预后:一项随机对照试验的研究设计

获取原文
           

摘要

Background The widespread and increasing use of oral anti-cancer medications has been ushered in by a rapidly increasing understanding of cancer pathophysiology. Furthermore, their popular ease of administration and potential cost savings has highlighted their central position in the health care system as a whole. These facts have heightened appreciation of the unique challenges associated with the use of oral anti-cancer medications; especially in the long-term use of these medications and the associated side effects that may impede optimal adherence to their use. Therefore, we developed ChemOtheRapy Assistant, CORA, a personalized mobile phone–based self-management application to help cancer patients on oral anti-cancer medications. Objective Our objective is to evaluate the effect of CORA on adherence to oral anti-cancer medications and other clinically relevant outcomes in the management of patients with renal and prostate cancer. Methods The study will be implemented as a 2-parallel group randomized controlled trial in 104 patients with renal or prostate cancer on oral anti-cancer medications over a 3-month study period. The intervention group will use CORA in addition to usual care for self-management while the control group will continue care as usual. Medication adherence will be measured objectively by a Medication Event Monitoring System device and is defined as the percentage of prescribed doses taken. We will also assess the effect of the intervention on cancer-related symptoms measured by the MD Anderson Symptom Inventory and unplanned hospital utilizations. Other outcomes that will be measured at study start, midpoint, and endpoint are health-related quality of life, cancer-related fatigue, and anxiety. Group differences in medication adherence will be examined by t tests or by non-parametric Mann-Whitney tests if the data are not normally distributed. Logistic regression will be used to identify potential predictors of adherence. Results We expect to have results for this study before the end of 2016. Conclusions This novel mobile phone–enabled, multimodal self-management and educational intervention could lead to improvements in clinical outcomes and serve as a foundation for future mHealth research in improving outcomes for patients on oral anti-cancer medications.
机译:背景技术通过对癌症病理生理学的快速理解,已经引起了口服抗癌药物的广泛和增加的使用。此外,他们普遍的易管理性和潜在的成本节省突出了他们在整个卫生保健系统中的中心地位。这些事实使人们更加认识到与口服抗癌药物的使用有关的独特挑战。特别是在长期使用这些药物以及可能妨碍最佳依从性的相关副作用方面。因此,我们开发了ChemOtheRapy Assistant,CORA,这是一种基于手机的个性化自我管理应用程序,可以帮助癌症患者使用口服抗癌药物。目的我们的目的是评估CORA对肾癌和前列腺癌患者治疗中口服抗癌药物依从性及其他临床相关结局的影响。方法该研究将作为一项2平行组的随机对照试验,在3个月的研究期间内,对104名肾癌或前列腺癌患者进行口服抗癌药物治疗。干预组除常规护理外,还将使用CORA进行自我管理,而对照组将照常继续护理。药物依从性将通过药物事件监测系统设备进行客观测量,并定义为所服用处方剂量的百分比。我们还将评估该干预对通过MD安德森症状清单和计划外医院利用所测得的癌症相关症状的影响。在研究开始,中点和终点进行测量的其他结果是与健康相关的生活质量,与癌症相关的疲劳和焦虑。如果数据不是正态分布的,则将通过t检验或通过非参数Mann-Whitney检验来检查药物依从性的群体差异。逻辑回归将用于识别依从性的潜在预测因子。结果我们希望在2016年底之前获得该研究的结果。结论这种新颖的具有移动电话功能的多模式自我管理和教育干预措施可能会导致临床结果的改善,并为未来mHealth研究改善疾病结局奠定基础。患者口服抗癌药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号